Objective: This work examined the effect of acute L-CPT1 expression on the regulation of palmitate oxidation and energy metabolism in intact functioning rat hearts for comparison with findings in hypertrophied hearts.
T he current study examines the consequences of mimicking the isoform shift in the carnitine palmitoyltransferase I (CPT1) enzyme that occurs in pathologically hypertrophied myocardium on fatty acid oxidation in the otherwise normal intact beating rat heart. [1] [2] [3] [4] CPT1 is responsible for the rate-limiting component of long chain fatty acid (LCFA) oxidation by cardiac mitochondria. We report the metabolic shifts induced by acute overexpression of the liver isoform of CPT1 (L-CPT1) that has been observed to be elevated in cardiomyocytes developing pathological hypertrophy. Reductions in LCFA oxidation are well-recognized to occur in hypertrophied myocardium and are associated with changes in the expression of associated metabolic enzymes. [1] [2] [3] [4] [5] [6] These changes influence the rate-limiting step of LCFA oxidation that occurs in the outer mitochondrial membrane at the enzyme, CPT1. Along with reporting reduced rates of LCFA oxidation in cardiac hypertrophy, our laboratory first demonstrated a shift in CPT1 isoform distribution toward L-CPT1 by reporting elevated L-CTP1 protein content in hypertrophied rat hearts. 3 The present study examines the direct influence of similarly elevated expression of L-CPT1 on the oxidative metabolism of the otherwise normal nonpathological rat heart attributable to acute targeted delivery and cardiac expression of the L-CPT1 gene.
The mitochondrial membrane is impermeable to LCFAs, which are oxidized via β-oxidation and the tricarboxylic acid (TCA) cycle in the inner matrix. CPT1 serves as a translocase for fatty acyl esters by spanning the outer mitochondrial membrane and catalyzing acyl group transfer from coenzyme A to carnitine. 7 There are 2 structural genes that encode CPT1, 1 for the liver, or a, isoform of the enzyme, and 1 for the muscle, or b, isoform. 1, 2, 7, 8 These CPT1 isoforms are differentially expressed among tissues that use LCFAs as a fuel, and both isoforms are coexpressed in heart muscle. In adult heart muscle, muscle CPT1 (M-CPT1) is the predominantly expressed isoform, with limited activity from L-CPT1. [1] [2] [3] [9] [10] [11] However, until recently, the actual content of L-CPT1 that is elevated in the hypertrophied heart, as opposed to transcript levels from myocardium or analysis activity in cultured neonatal cardiomyocytes, was not known. 2, 3, 12 The liver and muscle isoforms of CPT1 have different kinetic properties, with L-CPT1 being less sensitive to malonyl CoA inhibition and displaying a higher affinity for carnitine. 7, 9 Yet, LCFA oxidation is lower in hearts with elevated L-CPT1 content (ie, hypertrophied adult hearts and neonatal hearts) than in normal adult hearts displaying minimal L-CPT1 activity. [1] [2] [3] [4] [5] [6] 9, 11, 13, 14 Elevated L-CPT1 levels in cardiomyocytes, in culture, have been explained as a potential adaptive response based on the teleological argument that L-CPT1 expression serves the functional outcome of maintaining fatty acid oxidation, albeit reduced. 2 The link between increased L-CPT1 and reduced palmitate oxidation also is consistent with a reversion to fetal isoform expression of metabolic enzymes and reduced LCFA oxidation rates under conditions of limited carnitine availability in fetal and neonatal hearts. 1, 2, 9, 10, 13 These seemingly incongruent findings between L-CPT1 expression and LCFA oxidation also may suggest a multifactorial level of regulation of LCFA oxidation to produce the observed metabolic phenotypes. However, no previous work has examined the direct influence of isoform shifts in CPT1 on LCFA oxidation rates in the intact adult heart in the absence of disease.
Therefore, this study examined what effect acute overexpression of L-CPT1 has on energy metabolism in the adult rat heart after in vivo delivery and expression of exogenous L-CPT1 gene. The use of the acute overexpression model enabled an examination of metabolic adaptations to L-CPT1 expression and the direct influence of L-CPT1 expression on LCFA oxidation in the absence of developmental adaptations attributable to chronic overexpression. The aims of this study were to examine the effects of increased L-CPT1 content in the otherwise normal adult rat heart on rates of palmitate oxidation; to determine the effects of increased L-CPT1 expression on M-CPT1 expression in adult rat hearts; to compare the fraction of palmitate contributing to acetyl CoA formation in the TCA in hearts with acute overexpression of L-CPT1 compared with both sham-infected controls with normal CPT1 isoform distributions and with hearts with pressure overload hypertrophy; and to examine the potential responses in proteins indicative of the hypertrophic stimulus in hearts with acute overexpression of L-CPT1, sham-infected control hearts, and hypertrophied hearts. The outcome offers new insight into the complex integration of enzyme expression and activities within metabolic networks that are linked to changes in pathophysiological state.
Methods

Heart Models
All protocols and procedures involving animals were approved by the Animal Care Policies and Procedures Committee at the University of Illinois in Chicago (Institutional Animal Care and Use Committee accredited), and animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (National Institutes of Health Publication No. 85-23, revised 1996).
Adult rats (male, Sprague Dawley, 400-450 g) were anesthetized (pentobarbital, 50 mg/kg intraperitoneally, 1% isoflurane inhalation), and in vivo intracoronary perfusion of the heart was performed with either adenovirus carrying cDNA for the rat liver isoform of the carnitine palmitoyltransferase I (Adv.cmv.L-CPT1) at 8 × 10 12 viral particles/mL PBS (0.4 mL), adenovirus carrying scrambled cDNA (empty) at 8 × 10 12 viral particles/mL as a viral delivery control group, or 0.4 mL phosphate-buffered saline (PBS) as a sham control 15, 16 (Online Materials). The adenovirus expresses the liver isoform of the CPT1 gene (10 12 viral particles/mL PBS) under a cytomegalovirus (CMV) promoter. Use of the viral vector did not influence L-CPT1 expression in the absence of code for L-CPT1 (Online Figure II) .
In other groups, anesthetized rats received transverse aortic constriction to produce pressure overload or sham surgery, as previously described. 3, 6, 16 Transverse aortic constriction produces concentric cardiac hypertrophy and increased heart-to-body weight ratio within 10 weeks postsurgery. At 10 weeks postsurgery, experiments were performed on isolated hearts from these animals.
Hearts were excised from anesthetized rats (pentobarbital, 50 mg/kg intraperitoneal) at 72 hours after intracoronary perfusion or 10 weeks after transverse aortic constriction. Excised hearts were either immediately perfused or frozen for assays.
C Enrichment Protocols for Metabolic Flux Measurements
Rates of LCFA oxidation or the fraction of palmitate contributing to acetyl CoA synthesis for the TCA cycle were determined in isolated perfused rat hearts excised from rats that were anesthetized and heparinized (500 U/100 g intraperitoneal; L-CPT1, n=15; PBS sham, n=7). Similarly, hearts were perfused from rats subjected to transverse aortic constriction (n=14) or sham operation (n=11). Isolated hearts were perfused in a retrograde fashion at 37°C, as previously described, with modified Krebs-Henseleit buffer (116 mmol/L NaCl, 4 mmol/L KCl, 1.5 mmol/L CaCl 2 , 1.2 mmol/L MgSO 4 , and 1.2 mmol/L NaH 2 PO 4 , equilibrated with 95% O 2 /5% CO 2 with 0.4 mmol/L unlabeled palmitate/albumin complex [3:1 molar ratio] and 5 mmol/L glucose). 3, 6, 16 A water-filled latex balloon in the left ventricle was set to a diastolic pressure of 5 mm Hg and provided hemodynamic recordings (Powerlab; AD Instruments). Left ventricular developed pressure and heart rate were continuously recorded. After each perfusion, hearts were frozen for biochemical analyses. For palmitate oxidation, isolated hearts were initially supplied buffer containing unlabeled palmitate/albumin and glucose for 10 minutes to ensure metabolic equilibrium and for collection of background 13 C nuclear magnetic resonance (NMR) signals of naturally abundant 13 C (1.1%). At the start of each enrichment protocol, the perfusate was switched to buffer (1 L) containing [2,4,6,8,10,12,14,16-13 C 8 ] palmitate (0.4 mmol/L; Isotec) plus unlabeled glucose (5 mmol/L). Perfusion with 13 C-enriched media continued for 40 minutes. For metabolic flux measurements, a subset of these hearts (L-CPT1, n=10; PBS sham, n=5) were situated in a 20-mm NMR probe within a vertical 89-mm bore 9.4-T magnet. 31 TCA tricarboxylic acid measurements were acquired as described elsewhere. 3, 17 Energetic state was determined by 31 P NMR detection of phosphocreatine and ATP content. 3 Metabolic flux in the intact beating heart was determined during 13 C palmitate delivery to the intact rat heart ex vivo using well-described methods for kinetic analysis of the progressive 13 C enrichment of glutamate via NMR spectroscopy 3, 17 (Online Materials). Kinetic analysis provided TCA cycle flux, the interconversion rate between cytosolic glutamate and mitochondrial α-ketoglutarate via the oxoglutarate-malate carrier, and 13 C palmitate entry into the mitochondria as an index of CPT1 flux). Hearts from additional experimental groups of Adv.cmv.L-CPT1infected rats (n=7) and PBS-infused control rats (n=5) were perfused with unenriched palmitate (0.4 mmol/L) plus [1,6-13 C 2 ] glucose (5 mmol/L) to assess potential differences in glucose oxidation.
Tissue Biochemistry
Assays for glutamate, aspartate, citrate malate, and α-ketoglutarate were determined spectrophotometrically and fluorometrically. [17] [18] [19] [20] [21] Triacylglycerol was determined by colorimetry of processed lipid extracts (Wako Pure Chemical Industries). 6 Malonyl CoA was assayed by high-pressure liquid chromatography with ultraviolet detection. 22, 23 The percent of labeled acetyl CoA entering the TCA cycle was determined from in vitro 13 C NMR spectra. 6, 24 Enrichment of glutamate from [1,6-13 C 2 ] glucose was determined via 13 C NMR of in vitro tissue extracts and the relative contributions of 13 C-enriched glucose and the unlabeled ( 12 C) endogenous pool of glycogen determined via 1 H NMR of alanine enrichment. 3, 25 For Western blot assay of CPT1, hearts excised from both PBS shams (n=7) and L-CPT1 heart (n=3) were perfused with ice-cold mannitol, sucrose, EGTA (MSE) media containing, 220 mM mannitol, 70 mM sucrose, 2 mM ethylene glycol-bis(aminoethylether)tetraacetic acid (EGTA), 5 mM 3-(4-morpholino) propane sulfonic acid (MOPS), pH 7.4, 0.2% BSA and a protease inhibitor cocktail containing 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), E-64, bestatin, leupeptin, aprotinin, and sodium ethylenediaminetetraacetic acid (EDTA) (Sigma, St. Louis, MO) The left ventricle was minced and homogenized in 1 mL ice-cold MSE media and centrifuged at 15 000g for 15 minutes. Rat liver was used as a positive control for L-CPT1 content. Total homogenate protein concentration was determined from a standard curve (Bradford assay), and equivalent samples (80-100 μg protein) were dissolved in Laemmli buffer and then loaded and separated on a 7.5% NuPAGE Bis-Tris gel. Gel proteins were subsequently transferred onto a nitrocellulose membrane. Western blots were performed according to the standard techniques using human heart M-CPT1 Ab and rat liver L-CPT1 Ab. 3 Semiquantitative densitometric analysis was performed using the Bio-Rad Universal Hood and Quantity One software. Message level for atrial naturietic peptide (ANP) expression was determined after total RNA isolation by single extraction with an acid guanidinium thiocyanate-phenol-chloroform mixture. 3, 26 Myocardial contents of acetyl CoA carboxylase (ACC) 2 and phosphorylated ACC2 (P-ACC2, Ser 218) and malonyl CoA decarboxylase (MCD) were determined in the available myocardial tissue from L-CPT1 hearts (n=13), PBS shams (n=7), hypertrophied hearts (n=4), and sham-operated hearts (n=4). ACC2 and P-ACC2 were probed with corresponding antibodies, as previously described (Upstate Cell Signaling Technologies). 27 MCD was immunoblotted with an anti-MCD antibody (H2-40 antibody, prepared in-house) as detailed elsewhere. 27
Statistical Analysis
Intergroup statistics were analyzed using Student t test for comparison of 2 mean values and 1-way ANOVA analysis with the Tukey posttest for comparison of multiple group means. Statistical significance was established at 5% probability (P<0.05). All reported values are reported as averages±SEM.
Results
Response of CPT1 Expression to Exogenous L-CPT1 Gene Delivery
After adenoviral delivery of the exogenous gene for rat L-CPT1 to the in vivo heart, the level of L-CPT1 protein was increased in adv.cmv.L-CPT1-infected hearts 5-fold over L-CPT1 content in control hearts receiving sham infusions of PBS, as displayed in Figure 1 . 15, 16 The content of M-CPT1 remained unchanged in the presence of elevated L-CPT1 ( Figure  1 ). The level of L-CPT1 overexpression that was achieved was similar to the approximate 4-to 5-fold increase in L-CPT1 protein that was previously reported for hypertrophied rats. 3
Oxidative Rates and Metabolism of Palmitate in L-CPT1-Expressing Adult Rat Hearts
The functional workloads, as assessed by rate-pressure products (RPP) generated by the perfused hearts, were similar ( Figure 2 ), and thus the metabolic demand imposed by cardiac workload was the same in the sham and L-CPT1-expressing groups. Consequently, mitochondrial oxidative rates, as assessed by TCA cycle flux from dynamic-mode 13 C NMR of the beating hearts ( Figure 3A ), also were similar with either L-CPT1 (12.3 ± 1.0 μmol/min per gram of dry weight; mean±SE) expression or PBS infusion (15.0 ± 1.5).
However, despite similar rates of flux within the TCA cycle, the rate of palmitate oxidation in the intact hearts was unexpectedly reduced in hearts expressing L-CPT1 in comparison with PBS-infused controls. L-CPT1 expression produced a 30% reduction in the rate of palmitate oxidation compared with hearts receiving PBS ( Figure 3B ), indicating lower rates of flux through CPT1 in the hearts with elevated L-CPT1. 3 Palmitate oxidation was reduced similarly in hypertrophied hearts and hearts with increased L-CPT1 content, as shown by reductions in the formation of acetyl CoA entering the TCA cycle from β-oxidation of palmitate ( Figure 4 ). Figure 4A displays representative in vitro 13 C NMR spectra of the 4-carbon glutamate resonance in acid extracts of myocardium from an L-CPT1-expressing heart ( Figure 4A , right) and a PBS-infused control ( Figure 4A , left) displaying the visual and quantitative differences between multiple structures of the resonance signals that resulted because of differences in the oxidation of [2, 4, 6, 8, 10, 12, 14, C 8 ] palmitate. 6 From static measures of 13 C NMR spectra from myocardial extracts ( Figure 4A ), the fraction of exogenous 13 C-enriched palmitate contributing to acetyl CoA production within the mitochondria of isolated perfused hearts was reduced by 12% in myocardium that overexpressed L-CPT1 ( Figure 4B ) in comparison with PBS controls. This decline mimicked the same 12% reduction observed in hypertrophy hearts vs sham-operated hearts ( Figure 4C ). The fractional contribution from palmitate oxidation in L-CPT1-expressing hearts ( Figure 4B ) were lower than that of both PBS-infused hearts and hearts receiving vector containing scrambled DNA (empty). PBS-infused controls, control empty virus infusion, and sham aortic banding all resulted in similar 13 
Compensatory Increase in Glucose Oxidation
The reduced palmitate oxidation in hearts expressing L-CPT1 was compensated by increased glucose oxidation ( Figure 5 ). From combined 13 C and 1 H NMR, the oxidation in the TCA cycle of both exogenous 13 C-enriched and endogenous unlabeled ( 12 C) glucose to form glutamate was elevated by 60%. No evidence of elevated oxidation of endogenous myocardial triglyceride stores was apparent, with very similar triglyceride content between L-CPT1-expressing and control hearts (L-CPT1=25.7 ± 5.1 μmol/g dry weight; PBS=25.3 ± 5.0). These data demonstrate a compensatory increase in glucose oxidation in response to reduced LCFA oxidation.
Comparisons With Hypertrophy: ANP mRNA With L-CPT1 Overexpression
Although palmitate oxidation was reduced in L-CPT1expressing hearts to the extent of that observed in hypertrophied hearts (Figure 4 ), which also are known to have elevated L-CPT1, 3 the L-CPT1-expressing hearts showed no evidence of energetic or pathophysiological changes. Hypertrophied hearts have a well-characterized increase in mass and a reduction in bioenergetic state. 3, 6, [28] [29] [30] In contrast, heart weight was not elevated in L-CPT1-expressing hearts (L-CPT1=2.53 ± 0.07 g; PBS=2.60 ± 0.08 g), and the ratio of phosphocreatine to ATP content in these hearts (1.8 ± 0.2) from 31 P NMR was not reduced in comparison with PBS controls (1.7 ± 0.1). Also, whereas hypertrophied myocardium has been reported to display increased anaplerotic flux of 3 carbon intermediates into the TCA cycle through malic enzyme, the otherwise normal hearts that overexpressed L-CPT1 also displayed normal ratios of anaplerotic to citrate synthase flux (L-CPT1=0.052 ± 0.009; PBS=0.068 ± 0.004). These findings are all consistent with normal contractile work and TCA cycle flux.
Despite these indices of normal myocardial pathology, an unexpected finding was that of significantly elevated ANP message levels by 2-fold in the L-CPT1-overexpressing rat heart ( Figure 6 ). As previously published, mRNA levels of the marker for the hypertrophic response, ANP, are elevated in response to pressure overload in the rat heart. 3, 26 Although the elevation of ANP message was several-fold smaller than that observed in hypertrophied hearts after 10 weeks of aortic banding, the finding of elevated ANP expression in hearts acutely expressing L-CPT1 suggests a link between the metabolic activity of the heart, with induced switching to fetal or hypertrophic isoforms of CPT1 and initiation of hypertrophic signaling.
Acetyl CoA Carboxylase, Malonyl Decarboxylase, and Malonyl CoA Content
Malonyl CoA, understood to inhibit CPT1 activity, is produced at the outer mitochondrial membrane by ACC2 via carboxylation of acetyl CoA that is produced from oxidative metabolism. Although cytosolic ACC1 has been related to the production of malonyl CoA for LCFA synthesis and elongation, a process not as active in cardiomyocytes, ACC2 production of malonyl, in concert with MCD action, is understood to work in tandem to regulate malonyl CoA levels.
Interestingly, malonyl CoA content was similar between L-CPT1-expressing and hypertrophied hearts as with PBSinfused shams. The only measurable difference in malonyl CoA was between hypertrophied hearts and sham-operated hearts (sham), with the latter slightly elevated in comparison with all other groups (PBS=1.54 ± 0.14 nmol/g per wet tissue weight, n=7; L-CPT1=1.53 ± 0.09, n=13; hypertrophied=1.43 ± 0.07, n=4; sham=1.99 ± 0.17, n=4; P<0.05 vs hypertrophied).
Phosphorylation of ACC2 reduces activity, and thus total ACC2 content and phosphorylation levels were examined with relation to the reduced LCFA oxidation observed in hearts overexpressing L-CPT1. The content and phosphorylation level of ACC2, along with MCD levels, for hearts overexpressing L-CPT1 are shown in comparison with sham hearts receiving PBS infusion (Figure 7 ). Values for ACC2 in L-CPT1expressing hearts and PBS-infused controls are normalized to the total content of pyruvate carboxylase, an enzyme shown to not change in response to hypertrophy. 3, 6 Pyruvate carboxylase levels also were not different between hearts with L-CPT1 overexpression and PBS-infused controls (Online Materials and Online Figure I) . Although total ACC2 content was unaffected by L-CPT1 overexpression (Figure 7) , the level of ACC2 phosphorylated at serine 218 was reduced by 32% in the L-CPT1-expressing hearts (Figure 7) . The reduced level of phosphorylation is consistent with less inhibition, and thus a greater capacity for ACC2 to catalyze the production of malonyl CoA from acetyl CoA. [31] [32] [33] However, as shown in Figure  7 and as seen in other heart models and tissues that display changes in LCFA oxidation, malonyl CoA levels were not different between L-CPT1-expressing hearts and sham hearts receiving PBS infusion. 34, 35 Consistent with these findings are the similarity in MCD levels in the L-CPT1-expressing hearts and PBS sham-infused hearts (Figure 7) , and thus the regulatory processes that lowered LCFA oxidation with increased L-CPT1 expression are yet to be identified and are likely to involve other processes beyond malonyl CoA levels.
Hypertrophied hearts resulting from transverse aortic constriction also contained similar levels of total ACC2 as surgical sham hearts (Figure 8) . In contrast to L-CPT1-expressing hearts, the hypertrophied hearts displayed elevated ACC2 phosphorylation, although no direct comparison is available between the L-CPT1-expressing and hypertrophied hearts that were assayed separately. Together, the findings of ACC2 content and phosphorylation state and malonyl CoA content are consistent with a previous finding that demonstrated no directional correlation between LCFA oxidation rates and L-CPT1 content, whereas M-CPT1 content correlated more closely with LCFA oxidation rates. 36 Evidence for muscle type-specific sensitivity of CPT1 activity to malonyl CoA levels also exists and may shed some insight into the current lack of correlation between malonyl CoA content and LCFA oxidation in L-CPT1-expressing hearts. 37 The potential for alternative or yet unidentified mechanisms that mediate L-CPT1 activity are considered in the next section.
Discussion
With these current results, 3 conditions in the heart are now linked to elevation in L-CPT1 content in comparison with the normal adult myocardium: a developmental condition of higher L-CPT1 content in the fetal heart; a pathological condition of elevated L-CPT1 content in hypertrophied hearts; and the experimental condition, presented here, of acute increases in L-CPT1 content in the other normal but genetically altered adult rat heart. [1] [2] [3] 9 Each of these 3 conditions that produces elevated L-CPT1 in the heart and thus shifts the isoform distribution of CPT1 from muscle toward liver enzymes are now associated with reduced fatty acid oxidation and elevated carbohydrate metabolism. 3, 5, 6, 11, 13, 14, 38 Although suggested as an adaptation to maintain LCFA oxidation, L-CPT1 never has been associated with increased LCFA oxidation in cardiomyocytes. 2 Importantly, the current study reports on actual rates of palmitate oxidation observed from online 13 C NMR observations of beating hearts that are responding to an acute induction of L-CPT1 expression in the intact functioning heart.
We previously have reported the first observation of increased L-CPT1 protein expression in hypertrophied heats. 3 We demonstrated the inefficiency in energy metabolism as a consequence of the shift away from the high yield of ATP provided by LCFA in the absence of limited oxygen delivery and tissue PO 2 , as has been shown to be the case in the remodeled and hypertrophied heart. 39, 40 Recent findings specific to maladpative expression of malic enzyme-1 also indicate inefficient metabolism of carbohydrates in the hypertrophied heart that were not in evidence in the current study of nonpathological hearts with an isolated elevation of L-CTP1 expression. 3, 6 Thus, the current findings enable focus on the link between L-CPT1 expression in heart and LCFA oxidation, without the many overlaying complexities of the diseased myocardium. Interestingly, as discussed, L-CPT1 expression induced elevated ANP levels, a marker of the hypertrophic response, suggesting a direct link to the pathogenesis of cardiac hypertrophy.
Elevated expression of L-CPT1 in hypertrophied hearts coincided with a reduced rate of LCFA oxidation. 3, 6 Whereas the muscle isoform, M-CPT1, is predominant in heart, the liver isoform is upregulated in hypertrophy. Interestingly, the hearts studied during brief acute overexpression of L-CPT1 after cardiac-specific introduction of the exogenous gene also showed evidence of significantly increased glucose oxidation in replacement of lost LCFA oxidation.
Triacylglyceride content was not affected by the presence of additional L-CPT1, and with no evidence of increased LCFA contributions from stored triacylglycerol present, a general shift from LCFA to glucose oxidation is evident in supporting the otherwise normal cardiac workload of hearts overexpressing L-CPT1 (Figure 2) . Values for the contribution of 13 C palmitate to acetyl CoA production demonstrate that the presence of L-CPT1 was required to reduce palmitate oxidation and not the introduction of the viral vector, because hearts receiving vector containing the scrambled code (empty) showed control levels of acetyl CoA enrichment from 13 C palmitate. Thus, the induced expression of L-CPT1 in the intact heart produced a reduction in LCFA oxidation similar to that of hypertrophied hearts, and contrary to the expectation of elevated LCFA oxidation were the reduced sensitivity to malonyl CoA levels and elevated carnitine affinity, the sole determinants of L-CPT1 activity in the intact myocardium. 1, 9, 10 Interestingly, CPT1 activity in tissues containing predominantly L-CPT1 is not directly proportional to protein content, and thus our previous observations in both hypertrophied hearts and now the L-CPT1-overexpressing hearts also may reflect this lack of proportionality. 3, 36 Induced expression of the exogenous L-CPT1 gene produced CPT1 protein content changes in the rat heart that were similar to those reported in the hypertrophied rat heart, with a 4-to 5-fold increase in L-CPT1 protein and minimal change in the level of M-CPT1 protein. 3 Thus, the metabolic shifts between LCFA and glucose oxidation reported here correspond to a relative distribution of the liver and muscle isoforms of CPT1 that is representative of the hypertrophied heart. A relatively surprising finding was that of increased levels of a well-known marker of hypertrophic signaling, ANP expression, in hearts overexpressing L-CPT1, which did not occur in sham-infused hearts subjected to the same surgical procedure. Although ANP mRNA levels were a great deal higher in hearts that had been subjected to pressure overload for 10 weeks and that displayed pathological hypertrophy, the L-CPT1-expressing hearts exhibited ANP message levels that were already double those of the sham group within only 72 hours ( Figure 6 ). 3 This finding indicates a provocative link between metabolic regulation at the level of gene expression and induction of hypertrophic signaling pathways in the heart that are directionally similar to the metabolic phenotype and ANP expression in pathological cardiac hypertrophy.
The findings also suggest the action of alternative regulatory mechanisms for the activation of L-CPT1 vs M-CPT1 in the cardiomyocyte beyond the inhibitory effects of malonyl CoA, which are becoming increasing apparent in metabolic studies of both cardiac muscle and other tissue types. [34] [35] [36] [37] 41 Malonyl CoA content was similar between L-CPT1-expressing and PBS-infused hearts, despite clearly reduced LCFA oxidation in hearts overexpressing L-CPT1. Yet, in confirming the wellreported reduction in LCFA oxidation in hypertrophied hearts, the current findings also show malonyl CoA to be actually lower in the hypertrophied hearts with reduced LCFA oxidation, as is consistent with limited acetyl CoA production from LCFA oxidation. 41 Nevertheless, malonyl CoA content was similar between L-CPT1 hearts and hypertrophied hearts. The similar malonyl CoA content among these groups also is consistent with similar enzyme protein levels of malonyl decarboxylase and ACC2 between L-CPT1 hearts and PBS controls, as well as between hypertrophied hearts and surgical shams. The only distinctions appear in the level of ACC2 phosphorylation at serine 218 (P-ACC2), where L-CPT1 hearts displayed lowered P-ACC2 compared with PBS controls and hypertrophied hearts showed elevated P-ACC2 content.
Because phosphorylation inactivates ACC2 for production of malonyl CoA, the reduced P-ACC2 content in L-CPT1 hearts may be consistent with the observed reduction in palmitate oxidation but are not consistent with the unchanged malonyl CoA content compared with controls. Hypertrophied hearts displayed lower malonyl CoA levels compared with surgical sham hearts, yet P-ACC2 content was higher than in sham-operated hearts. If malonyl CoA is the inhibitory agent to affect CPT1, then irrespective of relative P-ACC2 content, the reduced palmitate oxidation in the L-CPT1 hearts and hypertrophied hearts is not related to ACC2 phosphorylation levels. Thus, although the P-ACC2 assay results remain the only data to suggest a differential downstream regulation of L-CPT1 activity between the L-CPT1 hearts and hypertrophied hearts, malonyl CoA content in L-CPT1 hearts similar to that of the PBS controls and hypertrophied hearts strongly suggests that other factors besides total tissue malonyl CoA content regulate the observed LCFA oxidation through CPT1. This leads to questions beyond the scope of this study regarding the role of ACC1 in the cytosol in contributing to the total malonyl CoA that is measured in such studies.
Recently published reports indicate no direct relationship between increased malonyl CoA content and reduced LCFA oxidation in the heart. 34, 41, 42 Whereas these recent studies demonstrating the absence of a link between malonyl CoA content and LCFA oxidation were performed on hearts with a predominantly normal distribution of M-CPT1 and L-CPT1 contents, the current findings suggest that L-CPT1 may be subject to additional levels of regulation that are yet to be fully identified. Kim et al 37 reported on a malonyl CoA-resistant level of palmitate oxidation in red vs white skeletal muscle preparations. Therefore, in light of the present findings and newly emerging considerations, we cannot rule out other factors such as posttranslational modifications invoked in the intact functioning myocardium that limit LCFA oxidation through L-CPT1 beyond malonyl CoA, although studies indicate this isoform is less responsive to malonyl CoA than M-CPT1 in culture cell preparations. 10 Beyond the regulation of CPT1 activity as previously described, but not yet well-characterized in the intact myocardium, the induction of increased L-CPT1 isoform content in the intact heart produced an anticipated reduction in both the rate of palmitate oxidation and the contribution of palmitate to β-oxidation for the production of tricarboxylic acid cycle intermediates within the energy yielding oxidative pathways of the mitochondria. The shift in isoform distribution between the liver and muscle isoforms present in these hearts, after acute delivery of the exogenous gene for L-CPT1, was similar to the distribution previously reported in the hypertrophied heart. Whereas L-CPT1 expression had no measurable effect on M-CPT1 content, this isoform shift in otherwise normal rat hearts produced a reduction in palmitate oxidation that recapitulated the phenotype of reduced LCFA oxidation in the hypertrophied hearts. Increased incorporation of isotope from 13 C-enriched glucose into the 4-carbon position of glutamate demonstrated elevated glucose oxidation in L-CPT1-expressing hearts, indicating a shift from LCFA oxidation to glucose oxidation. However, unlike hypertrophied hearts, L-CPT1 hearts did not display a change in the metabolic fate of glycolytic end products, with a shift toward the anaplerotic production of malate, which has been linked to elevated malic enzyme 1 content in cardiac hypertrophy. 3, 6 Rather, acute overexpression of L-CPT1 induced a reduction in palmitate oxidation, with a consequential and compensatory shift toward increased glucose oxidation to maintain energy demands.
Nevertheless, the link between L-CPT1 expression and the induction of metabolic remodeling in hypertrophied hearts has been demonstrated here to be a key component of altered LCFA oxidation. Elevated L-CPT1 is associated with provocative elevation of ANP message, a marker of hypertrophic signal induction, in the otherwise nonpathogenic myocardium. The implications of this work are that previous notions of L-CPT1 regulation are incomplete when applied to the intact functioning heart. The findings suggest that a single key metabolic shift, such as altered CPT1 isoform expression and distribution, in the transition to decompensation of the pressure-overloaded heart alone can induce the shift away from fatty acid oxidation. The consequences of an acute increase in L-CPT1 expression in the rat heart, as observed here, suggest intriguing links among enzyme activity, metabolic flux, and metabolite content, and the induction of signaling pathways. The latter finding of elevated ANP message in response to increased L-CPT1 content implies the need for closer investigation into influences of metabolic signaling on myocardial remodeling.
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What Is Known?
• Long chain fatty acids (LCFAs) are the preferred fuel for mitochondrial ATP synthesis in the heart, but hypertrophied and failing hearts, like fetal hearts, display a metabolic phenotype of reduced long chain fatty acid oxidation.
• The rate-limiting step of LCFA oxidation is determined by transport of LCFA into the mitochondria via carnitine palmitoyltransferase I (CPT1), which exists in 2 isoforms: the adult muscle CPT1 (M-CPT1) that predominates in cardiomyocytes and the liver CPT1 (L-CPT1), which is more highly expressed in the fetal heart.
• Hypertrophied and failing hearts express higher than normal levels of the liver isoform, as do fetal hearts in comparison with normal adult hearts.
What New Information Does This Article Contribute?
• Acute overexpression of L-CPT1 in otherwise normal rat hearts, via cardiacspecific delivery of an exogenous gene, decreased LCFA oxidation.
• LCFA oxidation was reduced in hearts expressing L-CPT1, suggesting other factors influence L-CPT1 activity in intact functioning hearts.
• Increased expression of L-CPT1 and lower rate of LCFA oxidation in normal hearts were associated with increases in a marker of cardiac hypertrophy, atrial natriuretic peptide (ANP).
This study challenges dogma regarding the role of CPT1 in cardiac hypertrophy. Our previous work indicates that the reversion to a fetal gene program in cardiac hypertrophy increased myocardial content of the fetal form of CPT1, the liver isoform, coexpressed with adult M-CPT1. Mimicking the hypertrophic isoform distribution of CPT1 in nonpathogenic hearts recapitulated the lower LCFA oxidation rates that occur with cardiac hypertrophy. Importantly, the induced metabolic change elevated ANP. These findings provide novel insights into the complex interrelationship of metabolic gene expression, regulation of LCFA oxidation, and the induction of the hypertrophic response.
Novelty and Significance
